

REMARKS

Interview Summary

The undersigned called the Examiner on May 28, 2007 to discuss the new matter rejection of claims based on the group $-S(O)N(T^{11})T^{22}$ in claims 6, 8-1-, 15 and 20. No agreement was reached.

Status of the Claims

Claims 1, 4, 6-10, 15, 16 and 20-22 are pending.

Claims 1, 4, 6-10, 15, 16 and 20-22 have been rejected under 35 U.S.C. 112, first and second paragraphs.

Claim 21 is allowed.

Claim 16 is objected to as depending from a rejected claim.

Amendment of the Specification

The Examiner has objected to the reinstated paragraph for misspelling heterocyclo; for not specifying the attachment of certain moieties; and for the presence of a variable (T^{15}) in a moiety which was the result of a typographical error. In response, the spelling of "heterocyclo" and moiety attachments have been designated as would be understood by one of skill in the art, and the aforementioned moiety has been deleted.

Applicants believe that the present amendments made to the Specification and Claims do not add new matter, nor do they broaden the scope of what is claimed.

Rejections maintained from Office Action mailed August 30, 2006

The Examiner appropriately maintained the rejection of claim 8 for the duplication of the 4- $NH_2C(=O)$ -benzyl moiety. Applicants have completed the deletion of this moiety herein (first referred to in the Amendment dated December 4, 2006) and request withdrawal of this rejection under 35 U.S.C. 112, second paragraph.

New Rejections under 35 U.S.C. 112 and objection

The Examiner has newly rejected claims 6, 8-10, 15 and 20 under 35 U.S.C. 112, first paragraph, for failure to comply with written description contending that $-NHS(O)(T^{11})T^{22}$ is not described in the specification with regard to the genus of Formula (Ia). In response, Applicants have canceled the group $-NHS(O)(T^{11})T^{22}$ in the definitions of T^{11} , T^{14} , T^{15} , T^{16} , T^{19} and T^{21} , and respectfully request withdrawal of written description rejection.

Also, the Examiner has rejected the claims for incomplete/improper amendment of R² in claim 1 (see March 8 Office Action, 7 a), b) and c) q)): misspelling of heterocyclo throughout the claims (see 7 d), e), g), h), m), n), and o); the existence of each variable T¹-T⁹; the designation of attachment of variables 7 i), j), k), and l); and the dependence of claim 4 on a canceled claim.

In response, Applicants have completed the intended amendment of R² (see Amendment dated December 4, 2006); corrected the spelling of heterocyclo throughout the claims; written out each variable T¹-T⁹ as T¹, T², T³, T⁴, T⁵, T⁶, T⁷, T⁸ and T⁹; and corrected the attachment designation of the variables referred to in 7 i), j), k), and l). Also, Claim 4 has been amended to depend from Claim 1.

Finally, the Examiner had objected to claim 16 as being dependent upon a rejected base claim. Though Applicants believe said base claims 1 and 15 are now allowable, in response to the Examiner's rejection claim 16 has been rewritten in independent form.

In summary, Applicants believe all the rejections of the claims under 35 USC 112, have been either addressed or rendered moot. Applicants respectfully request withdrawal of the written description and indefiniteness rejections and believe the claims are now in condition for allowance.

FEES

No fee should be due, however, if it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

The Examiner is invited to contact the undersigned by telephone, at the number listed below, if it is believed that a telephonic communication would facilitate the prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-5323

/Laurelee A. Duncan, Reg. No. 44,096/
Attorney for Applicants
Reg. No. 44,096

Date: July 8, 2007